New York Times Examines Research Efforts Into Pre-Exposure Prophylaxis
August 4, 2008
By the middle of next year, more people from around the world will be enrolled in trials to test pre-exposure prophylaxis as an HIV prevention method than in trials for HIV vaccine candidates or microbicides, according to a report released Sunday by the AIDS Vaccine Advocacy Coalition at the opening of the XVII International AIDS Conference in Mexico City, the New York Times reports. After "bleak findings" from trials testing other HIV prevention methods, including microbicides and HIV vaccines, many HIV/AIDS experts have said that PrEP is the most promising research in HIV prevention, the Times reports.
According to AVAC, even if PrEP is proven successful, it will need to be combined with other prevention measures, including safer sex practices and use of clean needles.
In addition, the findings are likely to raise additional questions, such as whether taking PrEP just before sexual contact can be effective in preventing HIV transmission, the report said (Altman, New York Times, 8/4).
The report also identifies five priority issues for PrEP:
"We cannot wait for the study results to begin to prepare for the optimal use and delivery of PrEP," Pedro Goicochea, an investigator for a PrEP study in Ecuador and Peru, said. He added, "Instead we should look ahead to consider all of the possible outcomes of these trials and make real plans for making PrEP available to those who can benefit from it as quickly and safely as possible if it is proven effective" (New York Times, 8/4).
Increase in Commercial Sex Work, Sexual Violence in Kenya Following Violence Will Undermine HIV/AIDS Efforts, AP/Google.com Reports
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.